Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update September 18, 2023 • 4:25 PM EDT
Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting September 5, 2023 • 8:00 AM EDT
Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023 August 17, 2023 • 5:26 PM EDT
Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C. July 19, 2023 • 8:00 AM EDT
Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001 June 28, 2023 • 4:15 PM EDT
Kintara Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference June 16, 2023 • 8:00 AM EDT
Kintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor Society May 19, 2023 • 8:30 AM EDT
Kintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate Update May 11, 2023 • 8:15 AM EDT